Abstract
A more complete profiling of vaginal microbial communities and their variability enables a more accurate description of women microbiome. However, there is a distinct lack of information regarding the Chinese women. Composition of the vaginal microbiota during pregnancy and 6 weeks postpartum of 454 Chinese women thus was characterized in this study by sequencing V3-V4 regions of the 16S ribosomal RNA (rRNA). It showed that the vaginal microbiome varied during pregnancy and postpartum in response to abortion history, hypertensive disorders (HBP), delivery mode and maternal age. Co-variation of 21 bacterial taxa, including Lactobacillus and two of its species, may account for the common characteristics of vaginal microbiome under different medical histories and pregnancy outcomes. On the contrary, discriminant bacteria were significantly different between premature rupture of membranes related preterm birth (PROM-PTB) and non-PROM related PTB, and community state type (CST) I without any predominant Lactobacillus species in microbiota was more prevalent during pregnancy in PROM-PTB, suggesting that specific bacteria could be considered to distinguish different types of PTB. Through adding the data from Chinese women, the study will enrich the knowledge of human microbiome and likewise contribute to a better understanding of the association between the vaginal microbiome and reproductive health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (81825019, 31722031, 31670119, 31870107), the Beijing Leading Talents in Science and Technology (Z181100006318008), the China Mega-Project on Infectious Disease Prevention (2018ZX10713002-002, 2018ZX10101003-002, 2018ZX10301401), and the National Key Research and Development Program of China (2016YFC1000705).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed with the approval of the Ethical Committee of Beijing Institute of Microbiology and Epidemiology and conducted according to the principles expressed in the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sequencing data has been submitted to GSA at the National Genomics Data Center, with the accession ID CRA002692. All data referred to in the manuscript would be made available upon request.
